{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010478","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.553254+00:00","generated_at":"2026-05-16T10:46:44.483336+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO","bullets":["Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.","LAL procedure volume 28,611 in Q4 (+10% QoQ) and 109,615 in FY2025 (+12% YoY).","Installed LDD base reached 1,134 as of Dec 31, 2025 (25 LDDs sold in Q4).","Cash & short-term investments ~$228.1M as of Dec 31, 2025.","Mark Wilterding appointed CFO effective Jan 11, 2026, replacing Shelley Thunen (consulting role)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010478","json":"https://secwatch.observer/filing/0001193125-26-010478.json","markdown":"https://secwatch.observer/filing/0001193125-26-010478.md","text":"https://secwatch.observer/filing/0001193125-26-010478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/0001193125-26-010478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526010478/rxst-20260111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:46:44.483336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}